Lexicon Beats Investor Suit Over Statements About Diabetes Drug

Published August 17, 2020

Lexicon Pharmaceuticals Inc. won’t have to face accusations of misleading investors about a new diabetes drug after a federal judge in Texas dismissed the would-be class suit.